单胺氧化酶抑制剂 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "单胺氧化酶抑制剂" in Chinese language version.

refsWebsite
Global rank Chinese rank
2nd place
23rd place
4th place
5th place
1st place
1st place
5th place
12th place
3rd place
8th place
149th place
292nd place
6th place
4th place
9,815th place
7,156th place
3,634th place
1,794th place
low place
low place
438th place
700th place
low place
low place
222nd place
216th place
low place
low place
447th place
581st place
low place
low place
low place
low place
low place
5,056th place
1,933rd place
1,288th place
low place
low place
34th place
129th place

archive.org

bltc.com

  • BLTC Research [1]. Rasagiline: a neuroprotective smart drug?. The Good Drug Guide. 2006 [2007-12-02]. (原始内容存档于2007-12-09). At dosages above around 2 mg per day, rasagiline loses its selectivity for MAO type B and also inhibits MAO type A. An MAO-B selective regimen does not cause significant tyramine potentiation, the dreaded 'cheese effect' common to users of older unselective and irreversible MAOIs who eat tyramine-rich foods. This will be taken with and without food. Thus, low-dosage rasagiline demands no special dietary restrictions. 

books.google.com

doi.org

dx.doi.org

druglib.com

elitenetpharmacy.com

  • BLTC Research [1]. Rasagiline: a neuroprotective smart drug?. The Good Drug Guide. 2006 [2007-12-02]. (原始内容存档于2007-12-09). At dosages above around 2 mg per day, rasagiline loses its selectivity for MAO type B and also inhibits MAO type A. An MAO-B selective regimen does not cause significant tyramine potentiation, the dreaded 'cheese effect' common to users of older unselective and irreversible MAOIs who eat tyramine-rich foods. This will be taken with and without food. Thus, low-dosage rasagiline demands no special dietary restrictions. 

fda.gov

mayoclinic.com

nih.gov

ncbi.nlm.nih.gov

onlinedigeditions.com

psychiatrictimes.com

psycom.net

rcpsych.org

bjp.rcpsych.org

sciencedirect.com

ucsd.edu

toxicology.ucsd.edu

usda.gov

naldc.nal.usda.gov

washingtonpost.com

web.archive.org

wiley.com

onlinelibrary.wiley.com

  • Rothschild R, Quitkin HM, Quitkin FM, Stewart JW, Ocepek-Welikson K, McGrath PJ, et al. A double-blind placebo-controlled comparison of phenelzine and imipramine in the treatment of bulimia in atypical depressives. International Journal of Eating Disorders [Internet]. 1994 [cited 2013 Oct 4];15(1):1–9. Available from: http://onlinelibrary.wiley.com/doi/10.1002/1098-108X(199401)15:1[永久失效連結]<1::AID-EAT2260150102>3.0.CO;2-E/abstract

wkhealth.com

pt.wkhealth.com

worldcat.org